Castleark Management LLC Buys 12,235 Shares of Omnicell, Inc. (NASDAQ:OMCL)
Castleark Management LLC grew its position in Omnicell, Inc. (NASDAQ:OMCL) by 9.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 144,422 shares of the company’s stock after purchasing an additional 12,235 shares during the period. Castleark Management LLC’s holdings in Omnicell were worth $12,425,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the company. PNC Financial Services Group Inc. grew its holdings in Omnicell by 709.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 231,236 shares of the company’s stock worth $18,694,000 after acquiring an additional 202,682 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Omnicell by 716.6% in the first quarter. JPMorgan Chase & Co. now owns 225,620 shares of the company’s stock worth $18,239,000 after purchasing an additional 197,990 shares during the last quarter. BlackRock Inc. grew its stake in shares of Omnicell by 2.7% during the 1st quarter. BlackRock Inc. now owns 6,068,905 shares of the company’s stock valued at $490,611,000 after purchasing an additional 162,222 shares during the period. Allianz Asset Management GmbH grew its stake in shares of Omnicell by 149.9% during the 2nd quarter. Allianz Asset Management GmbH now owns 268,657 shares of the company’s stock valued at $23,112,000 after purchasing an additional 161,136 shares during the period. Finally, OppenheimerFunds Inc. increased its position in shares of Omnicell by 40.3% during the 1st quarter. OppenheimerFunds Inc. now owns 440,006 shares of the company’s stock valued at $35,569,000 after purchasing an additional 126,437 shares during the last quarter. Institutional investors own 99.57% of the company’s stock.
OMCL has been the topic of several recent research reports. BidaskClub cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Thursday, June 27th. ValuEngine lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. Zacks Investment Research raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a report on Monday, July 29th. Finally, Craig Hallum upgraded shares of Omnicell from a “hold” rating to a “buy” rating and set a $85.00 price target on the stock in a research report on Friday, July 26th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $79.11.
NASDAQ:OMCL traded up $1.09 during mid-day trading on Wednesday, hitting $73.15. 2,288 shares of the company traded hands, compared to its average volume of 238,629. The company has a quick ratio of 1.54, a current ratio of 2.03 and a debt-to-equity ratio of 0.10. The stock’s fifty day moving average price is $71.61 and its 200-day moving average price is $78.79. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of 47.32, a price-to-earnings-growth ratio of 2.34 and a beta of 1.13. Omnicell, Inc. has a one year low of $56.96 and a one year high of $92.59.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.47 by $0.04. Omnicell had a return on equity of 11.85% and a net margin of 5.70%. The firm had revenue of $217.40 million for the quarter, compared to the consensus estimate of $214.13 million. During the same quarter last year, the company earned $0.46 earnings per share. The business’s revenue for the quarter was up 15.2% compared to the same quarter last year. Equities analysts predict that Omnicell, Inc. will post 2.05 EPS for the current year.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Article: Derivative
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.